Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Statera Biopharma Inc STAB

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.


GREY:STAB - Post by User

Bullboard Posts
Post by DallasTauruson Jul 02, 2007 7:19pm
335 Views
Post# 13027491

CBLI Gets BioTech Exposure

CBLI Gets BioTech ExposureCBLI Cited Sunday July 01,in a BioHealthInvestor.com "Interview: Investment Opportunities in Healthcare with Alan Brochstein". Alan Brochstein is a CFA with AB Analytical Services. In responding to a question, he noted, "I created a universe of stocks today with all of the U.S. based biotechs with market capitalization in excess of $50mm. It is clear why so many investors are attracted to the market, as the payoffs can be quite extreme. In fact, thus far this year, nine companies have gained in excess of 75%, including Opko Health (OPK), Celsion (CLN), Bionovo (BNVI), Onyx (ONXX), BioSante (BPA), Clevland Biolabs (CBLI), Seattle Genetics (SGEN), Biopure (BPUR) and the infamous Dendreon (DNDN)."
Bullboard Posts